Literature DB >> 21470866

Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.

Katsumi Kubota1, Hirotaka Kurebayashi, Hirotaka Miyachi, Masanori Tobe, Masako Onishi, Yoshiaki Isobe.   

Abstract

A series of tricyclic carboxylic acids having 6-amino-pyrimidine-2,4(1H,3H)-dione with piperazino or homopiperazino moiety linked by propylene, were synthesized and evaluated for their affinity toward human histamine H(1) receptor and Caco-2 cell permeability. Selected compounds were further evaluated for their oral anti-histaminic activity in mice, bioavailability in rats, and their anti-inflammatory activity in mice OVA-induced biphasic cutaneous reaction model. Among the compounds tested, dibenzoxazepine carboxylic acid 13b showed both histamine H(1) receptor antagonistic activity and anti-inflammatory activity in vivo. In addition, 13b exhibited low affinity toward α(1) receptor and low occupancy of H(1) receptor in the brain. It is therefore, believed that 13b is a potential candidate for development as 3rd generation anti-histamine.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21470866     DOI: 10.1016/j.bmc.2011.03.003

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  3 in total

1.  Design, synthesis and antifungal activity of (E)-3-acyl-5-(methoxyimino)-1,5-dihydrobenzo[e][1,2]oxazepin-4(3H)-one analogues.

Authors:  Dongyan Yang; Haixia Wang; Zhijin Fan; Zhengming Li; Shuang Zhou; Zesheng Hao; You Lv; Tatiana A Kalinina; Tatiana V Glukhareva
Journal:  Mol Divers       Date:  2020-01-21       Impact factor: 2.943

2.  Michael Reaction of 3-aAryl-2,4-Dicarboethoxy-5-Hydroxy-5-Methylcyclohexanones.

Authors:  Fawzia Zakaria El-Ablack; M A Metwally; A M Khalil
Journal:  Org Chem Int       Date:  2015-09-01

3.  Theoretical Study of the Geometry of Dibenzoazepine Analogues.

Authors:  Małgorzata Szymańska; Irena Majerz
Journal:  Molecules       Date:  2022-01-25       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.